Madrigal Pharmaceuticals posted Q1 2026 results today that landed above expectations on both lines — yet the stock fell 3% on the session to close at $502.47, and is down nearly 9% over the past month.
The disconnect between a clean beat and a negative price reaction is the week's central tension. Revenue of $311.3M topped the $302.3M consensus estimate. EPS of -$3.25 beat the -$3.60 estimate by a meaningful margin, ranking the company near the very top of its universe on EPS surprise history — the factor score sits at the 92nd percentile. Still, shares drifted lower. The company also announced a licensing agreement for ARO-PNPLA3 alongside the results, signalling active pipeline expansion beyond Rezdiffra. The next earnings event is pencilled in for June 17, giving the market roughly six weeks to re-engage with the MASH growth story.
Short interest at 17.8% of free float is meaningful but not the defining variable here. The position has grown modestly — up around 2.2% over the past month — but drifted marginally lower on the week. Days-to-cover runs at 12.7 by the latest official FINRA data, a figure that reflects how thinly traded the stock is relative to its short base, not a fresh squeeze dynamic. Borrow availability has eased since early April, when it was tighter, and cost to borrow remains very low at 0.46% annually — shorts face virtually no carry pressure. The borrow market is loose enough that the short position is easily financed, and there is no immediate mechanical pressure forcing a cover.
Options positioning reinforces the bullish lean on this stock. The put/call ratio is 0.25, well below its 20-day average of 0.28 and close to the 52-week low of 0.235. That means call demand is dominant. The z-score is negative at -0.70, confirming calls are running hotter than usual relative to puts. Notably, the PCR had been considerably higher through late March and early April — readings above 0.38 to 0.40 were common — before dropping sharply from late April onward. Options traders have clearly rotated toward upside positioning heading into and through this earnings period.
The Street retains a constructive tilt, though targets have converged around a softer midpoint after a period of aggressive upgrades. Consensus is Buy, with a mean price target of $655.85 against the current price of $502.47 — implying roughly 30% upside. HC Wainwright reiterated Buy and maintained a $620 target today. The most ambitious call on the board is from Barclays, which initiated coverage with Overweight and a $964 target in late January; Citizens and Piper Sandler also carry targets north of $700. The outlier is Bank of America, which sits at Neutral with a $529 target set in February — barely above where the stock trades now, reflecting a more cautious view on Q1 seasonality headwinds and gross-to-net pressure. The broad case for the bulls is Rezdiffra's role as the established oral backbone for MASH treatment, with combination therapy potential and a major outcomes trial readout due in 2027 and 2028. The bears point to gross-to-net contracting costs eating into near-term margins and the ever-present risk of competitive entrants into the MASH space.
On the ownership side, the register is concentrated and largely committed. Baker Bros. Advisors holds 9.3% and RTW Investments 8.7%, both with no reported change at end-December. Avoro Capital trimmed slightly (down ~25,500 shares) while Paulson & Co. cut by 200,000 shares — the more notable institutional adjustment. Vanguard and BlackRock both added modestly through Q1. Inside the company, the most recent trades on record are from early March, when the CEO, CFO, Founder Rebecca Taub, and the Chief Commercial Officer all sold modest amounts — largely routine comp-related disposals at prices in the $427–$438 range, well below where the stock trades today.
What to watch next: the June 17 readout will test whether the Q1 revenue trajectory continues or whether gross-to-net headwinds compress the ramp more materially than bulls expect — making guidance commentary on Rezdiffra penetration in specialist care the key variable in the next cycle.
See the live data behind this article on ORTEX.
Open MDGL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
